)
Zentalis Pharmaceuticals (ZNTL) investor relations material
Zentalis Pharmaceuticals Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Annual meeting scheduled for June 16, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 15, 2026.
Voting matters and shareholder proposals
Election of two Class III Directors, David Johnson and Jan Skvarka, Ph.D., to serve until the 2029 annual meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation for named executive officers.
Board recommends voting in favor of all proposals.
Board of directors and corporate governance
Board nominees for Class III Directors are presented for election, with terms expiring in 2029.
- Azenosertib shows >30% response in Cyclin E1+ PROC, advancing toward late 2026 approval.ZNTL
Corporate presentation7 May 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with strong governance.ZNTL
Proxy filing30 Apr 2026 - Azenosertib advances in ovarian cancer with pivotal trials and new combination strategies underway.ZNTL
Leerink Global Healthcare Conference 202629 Apr 2026 - Advanced late-stage azenosertib trials and reduced net loss, maintaining strong cash runway.ZNTL
Q4 202526 Mar 2026 - Azenosertib shows >30% ORR and ~6 months mDOR in Cyclin E1+ PROC, advancing to Phase 3.ZNTL
Corporate presentation13 Mar 2026 - Azenosertib shows promise for PROC patients, with pivotal trials progressing toward 2026 readouts.ZNTL
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Azenosertib advances as an oral, non-chemo therapy for PROC with pivotal trials and FDA alignment.ZNTL
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026 - Azenosertib targets platinum-resistant ovarian cancer with high cyclin E1, advancing via adaptive trials.ZNTL
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026 - FDA paused new enrollment in azenosertib monotherapy trials after sepsis deaths; key data due in 2H 2024.ZNTL
Study Update3 Feb 2026
Next Zentalis Pharmaceuticals earnings date
Next Zentalis Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)